UNSPSC 51385005: Zomepirac sodium anhydrous

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C15H13ClNO3.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DA5B6IWF46, chemically known as 1h-pyrrole-2-acetic acid, 5-(4-chlorobenzoyl)-1,4-dimethyl-, sodium salt (1:1), but more generally known as zomepirac sodium anhydrous, which bears US NIH Compound Identifier 47290. European Medicines Agency schedules zomepirac sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00185MIG.

Most nations, for tariff purposes, schedule zomepirac sodium anhydrous under HS 29339990. SMILES: CC1CC(N(C1C(=O)C2CCC(CC2)CL)C)CC(=O)[O-].[NA+].

UNSPSC 51385005 Zomepirac sodium anhydrous is a Commodity code that does not align with the recent state and local contract opportunities posted under it. The three most recent opportunities solicited naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products (Minnesota Multistate Cooperative Purchasing Alliance). None of these solicitations seek zomepirac sodium anhydrous, an NSAID pain medication. The code shows no relevant recent activity that reflects its nominal product scope.

State and local governments have instead posted demand for emergency naloxone procurement, pharmacy benefit program innovation, and generic pharmaceutical contracting through established cooperative purchasing vehicles. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Geographic activity appears concentrated in Florida, Texas, and Minnesota, with Oregon participating through MMCAP. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; Texas HHS issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct manufacturer prescription programs; and MMCAP posted RFP S1070000015802 on January 20, 2026, with responses due March 26, 2026, for generic pharmaceuticals and OTC products through authorized wholesalers. The mismatch between the code's name and actual procurement activity suggests either a classification error in the source data or minimal zomepirac sodium anhydrous demand in recent state and local government purchasing.